Modulation of CCR4 function
View Patent ↗Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.
1. A method for treating a disease or condition selected from asthma, atopic dermatitis, atherosclerosis, multiple sclerosis, rheumatoid arthritis and HIV infection in a subject, said method comprising administering to a subject in need of such treatment an effective amount of a compound of formula (I):
or a pharmaceutically acceptable salt thereof, wherein
W is naphthyl;
X is S;
Y is NH;
Z is N;
R 1 and R 2 are independently selected from H, halogen, CN, CO 2 R′, CONR′R″ and (C 1 -C 8 )alkyl, wherein R′ and R″ are independently selected from H, (C 1 -C 8 )alkyl and aryl, and when R′ and R″ are attached to nitrogen atom, they may be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring.
2. A method in accordance with claim 1 , wherein said compound is
3. A method in accordance with claim 1 , wherein said compound is
4. A method in accordance with claim 1 , wherein said compound is selected from the group consisting of:
5. A method in accordance with claim 1 , wherein said compound is
6. A method in accordance with claim 1 , wherein said W is naphthyl.
7. A method in accordance with claim 1 , wherein said condition or disease is atopic dermatitis.
8. A method in accordance with claim 1 , wherein said condition or disease is asthma.
9. A method in accordance with claim 1 , wherein said condition or disease is rheumatoid arthritis.
10. A method in accordance with claim 1 , wherein said condition or disease is multiple sclerosis.
11. A method in accordance with claim 1 , wherein said condition or disease is atherosclerosis.
12. A method in accordance with claim 1 , wherein said disease or condition is atopic dermatitis and said compound is used alone or in combination with at least one therapeutic agent selected from a lubricant and corticosteroid.
13. A method in accordance with claim 1 , wherein said condition or disease is asthma and said compound is used alone or in combination with at least one therapeutic agent selected from a β2-agonist and a corticosteroid.
14. A method in accordance with claim 1 , wherein said compound interferes with the interaction between CCR4 and a ligand.
15. A method in accordance with claim 1 , wherein said administration is oral or intravenous.
16. A method in accordance with claim 1 , wherein said subject is selected from the group consisting of human, rat, dog, cow, horse, and mouse.
17. A method in accordance with claim 1 , wherein said subject is human.
18. A method in accordance with claim 1 , wherein said disease or condition is HIV infection.